Company Overview and News

1
Tiffany's (TIF) Q2 Earnings Likely to Increase: Here's Why

2018-08-27 zacks
Tiffany & Co. (TIF - Free Report) is slated to report second-quarter fiscal 2018 results on Aug 28. In the trailing four quarters, this designer, manufacturer and retailer of jewelry and other items has outperformed the Zacks Consensus Estimate by an average of 12%. In the last reported quarter, the company delivered a positive earnings surprise of 35.7%. Investors are counting on another estimate beat by Tiffany in the to-be-reported quarter.
MIK PVH AEO LUXTY

 
Luxottica Group, S.p.a. ADR (LUXTY) on Q2 2018 Results - Earnings Call Transcript

2018-07-23 seekingalpha
Luxottica Group, S.p.a. ADR (OTCPK:LUXTY) Q2 2018 Earnings Conference Call July 23, 2018 10:00 AM ET
LUXTY

 
Luxottica Group, S.p.a. ADR 2018 Q2 - Results - Earnings Call Slides

2018-07-23 seekingalpha
The following slide deck was published by Luxottica Group, S.p.a. ADR in conjunction with their 2018 Q2 earnings call.
LUXTY

 
US stock index futures: Political turmoil bubbles away; earnings loom

2018-07-23 cnbc
U.S. stock index futures pulled back ahead of Monday’s open, as investors monitored developments seeping out of the corporate and political spheres.
ITW LUXTY

13
Tiffany's (TIF) Omnichannel, Product Portfolio to Lift Sales

2018-06-27 zacks - 1
Industry experts believe that the luxury goods market is likely to remain healthy, courtesy of steady economic growth, higher consumer confidence and rising disposable income. Given this scenario, it will be wise to focus on some luxury goods’ stocks. Here we have highlighted one such stock Tiffany & Co. (TIF - Free Report) , which holds a significant position in the world jewelry market due to its distinctive brand appeal.
MOV GOOS FOSL LUXTY

2
3 Reasons Why You Should Snap Up Tiffany (TIF) Right Now

2018-06-15 zacks
Tiffany & Co. (TIF) is flexing muscle to counter competition in the jewelry industry. The company, which has a long-term expected earnings growth rate of 11.8%, is banking on several strategic initiatives to enhance customer base.
SCVL URBN FOSL LUXTY

 
Ray-Ban Just Dropped a $500 Pair of Aviators Plated in 24K Gold - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LUXTY

 
Will Tiffany (TIF) Manage to See Higher Earnings in Q1?

2018-05-21 zacks
Tiffany & Co. (TIF - Free Report) is slated to report first-quarter fiscal 2018 results on May 23. In the trailing four quarters, this designer, manufacturer and retailer of jewelry and other items has outperformed the Zacks Consensus Estimate by an average of 4.5%. In the last reported quarter, the company delivered a positive earnings surprise of 2.5%. Investors are counting on another estimate beat by Tiffany in the to-be-reported quarter.
LUXTY

 
Luxottica (LUXTY) Q1 2018 Sales - Slideshow

2018-04-30 seekingalpha
The following slide deck was published by Luxottica Group, S.p.a. ADR in conjunction with this event.
LUXTY

1
With a Glance Backward, Brooks Brothers Looks to the Future - The New York Times

2018-04-23 nytimes
In early 2002, just a few months after he officially took over as the new owner and chief executive officer of Brooks Brothers, Claudio Del Vecchio confronted the reality that the classic American retailer had largely lost its way.
RL NYTAB LUXTY

52
Tiffany Strategizes to Lift Sales, Innovates to Woo Buyers

2018-04-18 zacks
As competition is intensifying in the retail space, Tiffany & Co. (TIF - Free Report) is leaving no stone unturned to drive revenues. The company, which has a long-term expected earnings growth rate of 11.2%, is banking on several strategic initiatives to enhance customer base. The company's strategic endeavors have helped the stock to gain 8.5% compared with the industry’s decline of 1.2% in the past six months.
JWN ABX KSS M ABX LUXTY

103
'Very, very good' earnings season risks being overshadowed by trade, politics in week ahead

2018-04-13 cnbc
Trade talk and politics could hang over the market in the coming week, even with a blast of earnings news providing a bright spot.
WFCNP DB NTRSP DGX UFPI NTRS MS KSU WFC STT GEC GE STLD UMPQ SYF BHI URI GNE TRI LUXTY

7
New Look Vision Group - A Closer Look At A Rising Presence

2018-03-14 seekingalpha
New Look Vision's growth strategy will allow them to take advantage of their economies of scale, as well as secure its position within the increasingly consolidated industry of optical retail.
EYE SAFLF BOSSY FLMNY KATE SAFLY HUGPF FLMNF BCI LUXTY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...